Rahul D. Ballal Sells 53,400 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rahul D. Ballal sold 53,400 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $23.95, for a total value of $1,278,930.00. Following the completion of the sale, the director now owns 22,341 shares in the company, valued at $535,066.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Enliven Therapeutics Stock Down 11.5 %

NASDAQ:ELVN opened at $21.08 on Friday. The firm has a market cap of $868.50 million, a PE ratio of -9.63 and a beta of 1.06. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The company’s 50-day moving average price is $16.77 and its two-hundred day moving average price is $14.20.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. On average, research analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. AJOVista LLC acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $28,000. Tower Research Capital LLC TRC bought a new stake in Enliven Therapeutics during the 1st quarter worth about $36,000. Ameritas Investment Partners Inc. acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $39,000. Royal Bank of Canada raised its stake in shares of Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after acquiring an additional 2,589 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $66,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Mizuho initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.